Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (6): 485-492.doi: 10.35541/cjd.20201201
• Original Articles • Previous Articles Next Articles
Wang Xiaoyu1, Wang Wenhui1, Dai Hui2, Xie Jiawei2, Wang Guanyu1, Guo Jinzhu1, Zhang Hua3, Wang Xiujuan4, Xu Yongsheng4, Zhang Chunlei1
Received:
2020-12-15
Revised:
2021-03-09
Online:
2021-06-15
Published:
2021-05-31
Contact:
Zhang Chunlei
E-mail:zhangchunleius@163.com
Supported by:
Wang Xiaoyu, Wang Wenhui, Dai Hui, Xie Jiawei, Wang Guanyu, Guo Jinzhu, Zhang Hua, Wang Xiujuan, Xu Yongsheng, Zhang Chunlei. Therapeutic effect of human umbilical cord mesenchymal stem cells on imiquimod?induced psoriasis-like mouse models[J]. Chinese Journal of Dermatology, 2021, 54(6): 485-492.doi:10.35541/cjd.20201201
[1] | Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft⁃versus⁃host disease[J]. Stem Cell Res Ther, 2019,10(1):182. doi: 10.1186/s13287⁃019⁃1287⁃9. |
[2] | Yun CW, Lee SH. Potential and therapeutic efficacy of cell⁃based therapy using mesenchymal stem cells for acute/chronic kidney disease[J]. Int J Mol Sci, 2019,20(7):1619. doi: 10. 3390/ijms20071619. |
[3] | Päth G, Perakakis N, Mantzoros CS, et al. Stem cells in the treatment of diabetes mellitus ⁃ focus on mesenchymal stem cells[J]. Metabolism, 2019,90:1⁃15. doi: 10.1016/j.metabol.2018.10. 005. |
[4] | Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study[J]. Arthritis Res Ther, 2014,16(2):R79. doi: 10.1186/ar4520. |
[5] | Wang L, Huang S, Li S, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study[J]. Drug Des Devel Ther, 2019,13:4331⁃4340. doi: 10.2147/DDDT.S225613. |
[6] | Chen H, Niu JW, Ning HM, et al. Treatment of psoriasis with mesenchymal stem cells[J]. Am J Med, 2016,129(3):e13⁃e14. doi: 10.1016/j.amjmed.2015.11.001. |
[7] | Seetharaman R, Mahmood A, Kshatriya P, et al. Mesenchymal stem cell conditioned media ameliorate psoriasis vulgaris: a case study[J]. Case Rep Dermatol Med, 2019,2019:8309103. doi: 10.1155/2019/8309103. |
[8] | De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose⁃derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report[J]. Cell Transplant, 2016,25(11):2063⁃2069. doi: 10.3727/096368916X 691998. |
[9] | 杨莹, 李政楠, 王秀娟, 等. 脐带来源间充质干细胞的免疫抑制功能研究[J]. 药物评价研究, 2020,43(12):2385⁃2389. doi: 10.7501/j.issn.1674⁃6376.2020.12.005. |
[10] | van der Fits L, Mourits S, Voerman JS, et al. Imiquimod⁃induced psoriasis⁃like skin inflammation in mice is mediated via the IL⁃23/IL⁃17 axis[J]. J Immunol, 2009,182(9):5836⁃5845. doi: 10. 4049/jimmunol.0802999. |
[11] | Campanati A, Consales V, Orciani M, et al. Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives[J]. Psoriasis (Auckl), 2017,7:73⁃85. doi: 10.2147/PTT.S108311. |
[12] | Wang Q, Yang Q, Wang Z, et al. Comparative analysis of human mesenchymal stem cells from fetal⁃bone marrow, adipose tissue, and Warton′s jelly as sources of cell immunomodulatory therapy[J]. Hum Vaccin Immunother, 2016,12(1):85⁃96. doi: 10.1080/21645515.2015.1030549. |
[13] | Bonfield TL, Nolan Koloze MT, Lennon DP, et al. Defining human mesenchymal stem cell efficacy in vivo[J]. J Inflamm (Lond), 2010,7:51. doi: 10.1186/1476⁃9255⁃7⁃51. |
[14] | Shin TH, Kim HS, Choi SW, et al. Mesenchymal stem cell therapy for inflammatory skin diseases: clinical potential and mode of action[J]. Int J Mol Sci, 2017,18(2):244. doi: 10.3390/ijms18020244. |
[15] | 王燕芹, 李新新, 薛海波, 等. γ分泌酶抑制剂阻断Notch⁃Hes1信号通路对银屑病样皮炎小鼠γδT17细胞表达的影响[J]. 中华皮肤科杂志, 2019,52(11):801⁃807. doi: 10.35541/cjd. 20190241. |
[16] | 黄钟洲, 陈小彦, 徐敏, 等. 咪喹莫特诱导的银屑病样小鼠模型的组织学及免疫学特征初步探究[J]. 皮肤性病诊疗学杂志, 2019,26(2):61⁃66. doi: 10.3969/j.issn.1674⁃8468.2019.02. 001. |
[17] | Dong C. Seventeen on inflammation[J]. Nat Immunol, 2020,21(8):821⁃822. doi: 10.1038/s41590⁃020⁃0649⁃x. |
[18] | Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17⁃producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol, 2005,6(11):1123⁃1132. doi: 10.1038/ni1254. |
[19] | Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL⁃17+ T helper cells[J]. Cell, 2006,126(6):1121⁃1133. doi: 10.1016/j.cell.2006.07.035. |
[20] | Ghoreschi K, Mrowietz U, Röcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses[J]. J Mol Med (Berl), 2003,81(8):471⁃480. doi: 10.1007/s00109⁃003⁃0460⁃9. |
[21] | Szabo SJ, Kim ST, Costa GL, et al. Pillars article: a novel transcription factor, T⁃bet, directs Th1 lineage commitment. Cell. 2000. 100: 655⁃669[J]. J Immunol, 2015,194(7):2961⁃2975. |
[22] | Mullen AC, High FA, Hutchins AS, et al. Role of T⁃bet in commitment of TH1 cells before IL⁃12⁃dependent selection[J]. Science, 2001,292(5523):1907⁃1910. doi: 10.1126/science.105 9835. |
[23] | Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T⁃bet in TH1 lineage commitment and IFN⁃gamma production in CD4 and CD8 T cells[J]. Science, 2002,295(5553):338⁃342. doi: 10.1126/science.1065543. |
[24] | Sah SK, Park KH, Yun CO, et al. Effects of human mesenchymal stem cells transduced with superoxide dismutase on imiquimod⁃induced psoriasis⁃like skin inflammation in mice[J]. Antioxid Redox Signal, 2016,24(5):233⁃248. doi: 10.1089/ars.2015.6368. |
[25] | Ghannam S, Pène J, Moquet⁃Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype[J]. J Immunol, 2010,185(1):302⁃312. doi: 10.4049/jimmunol.0902007. |
[26] | Liu C, Liu H, Lu C, et al. Kaempferol attenuates imiquimod⁃induced psoriatic skin inflammation in a mouse model[J]. Clin Exp Immunol, 2019,198(3):403⁃415. doi: 10.1111/cei.13363. |
[27] | Krueger JG, Wharton KA Jr, Schlitt T, et al. IL⁃17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis[J]. J Allergy Clin Immunol, 2019,144(3):750⁃763. doi: 10.1016/j.jaci.2019.04.029. |
[28] | Solberg SM, Sandvik LF, Eidsheim M, et al. Serum cytokine measurements and biological therapy of psoriasis ⁃ prospects for personalized treatment?[J]. Scand J Immunol, 2018,88(6):e12725. doi: 10.1111/sji.12725. |
[29] | 张莉, 陈利红, 李霞, 等. IL⁃17A单克隆抗体治疗诱导期对寻常性银屑病患者血清细胞因子的影响[J]. 中国皮肤性病学杂志, 2020,34(11):1249⁃1254. doi: 10.13735/j.cjdv.1001⁃7089. 202002067. |
[30] | Haider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF⁃regulated genes linked to psoriasis transcriptome[J]. J Invest Dermatol, 2008,128(3):655⁃666. doi: 10.1038/sj.jid.5701064. |
[31] | Lowes MA, Chamian F, Abello MV, et al. Increase in TNF⁃alpha and inducible nitric oxide synthase⁃expressing dendritic cells in psoriasis and reduction with efalizumab (anti⁃CD11a)[J]. Proc Natl Acad Sci U S A, 2005,102(52):19057⁃19062. doi: 10.1073/pnas.0509736102. |
[32] | Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL⁃17[J]. Cytokine Growth Factor Rev, 2015,26(1):25⁃33. doi: 10.1016/j.cytogfr.2014.10. 009. |
[1] | Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245. |
[2] | Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263. |
[3] | Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250. |
[4] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
[5] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022) [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
[6] | Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644. |
[7] | Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184. |
[8] | Zhao Ying, Wang Juanjuan, Ji Jiang, Su Wenxing, Wei Yuqian, Leng Hong, Ding Yujie, Shi Xin. Interleukin-17A-mediated psoriasis and cardiovascular comorbidities [J]. Chinese Journal of Dermatology, 2022, 55(1): 76-79. |
[9] | Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75. |
[10] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420. |
[11] | Lin Luyang, Chen Zhengliang, Zhang Xibao. Major immune-related cells in psoriasis vulgaris lesions [J]. Chinese Journal of Dermatology, 2021, 54(9): 830-834. |
[12] | Lan Xiaoou, Wang Qiang, Li Shangyun, Sun Xiaodong, Song Danyang, Li Jiawei, Song Guoqiang, Hu Lanting, Geng Long. Topical shikonin: intervention effect on an imiquimod-induced psoriasis-like mouse model and influence on CEBPD expression [J]. Chinese Journal of Dermatology, 2021, 54(8): 696-701. |
[13] | Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596. |
[14] | Committee on Psoriasis, Chinese Society of Dermatology, Committee on Children, Chinese Society of Dermatology. Consensus on the diagnosis and treatment of childhood psoriasis in China (2021) [J]. Chinese Journal of Dermatology, 2021, 54(7): 559-581. |
[15] | Ying Jieya, Xiang Wenzhong, Song Xiuzu. Metabolic syndrome and skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(7): 642-645. |
|